Signal Transducers and Activators of Transcription (STATs) are a family of cytoplasmic proteins with roles as signal messengers and transcription factors that participate in normal cellular responses to cytokines and growth factors. Frequently, however, abnormal activity of certain STAT family members, particularly Stat3 and Stat5, is associated with a wide variety of human malignancies, including hematologic, breast, head and neck, and prostate cancers. Application of molecular biology and pharmacology tools in disease-relevant models has con®rmed Stat3 as having a causal role in oncogenesis, and provided validation of Stat3 as a target for cancer drug discovery and therapeutic intervention. Futhermore, a constitutively-active mutant form of Stat3 is sucient to induce oncogenic transformation of cells, which form tumors in vivo. Constitutive activation of Stat3 signaling is accompanied by upregulation of cyclin D1, c-Myc, and Bcl-x, changes consistent with subversion of normal cellular growth and survival control mechanisms. Block of constitutive Stat3 signaling results in growth inhibition and apoptosis of Stat3-positive tumor cells in vitro and in vivo. The observed dependence of certain tumors on constitutive Stat3 signaling for growth and survival has wide implications for cancer therapy, oering the potential for preferential tumor cell killing. This review evaluates constitutive Stat3 activation as a`cancer-causing' factor, and proposes a number of molecular strategies for targeting Stat3 signaling for therapeutic intervention. Oncogene (2000) 19, 6613 ± 6626.
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STAT proteins: an overview
STATs were originally discovered as latent cytoplasmic transcription factors that mediate cellular responses to diverse cytokines and growth factors Darnell et al., 1994; Horvath and Darnell, 1997; Ihle and Kerr, 1995; Schindler and Darnell, 1995; Stark et al., 1998) . STATs are activated by tyrosine phosphorylation following the binding of cytokines or growth factors to cognate receptors on the cell surface ( Figure  1 ). Tyrosine kinases that mediate STAT activation include growth factor receptors and cytoplasmic tyrosine kinases, particularly Janus kinase (JAK) and Src kinase families. Once tyrosine phosphorylated, two STAT monomers form dimers through reciprocal phosphotyrosine-SH2 interactions, translocate to the nucleus, and bind to STAT-speci®c DNA-response elements of target genes to induce gene transcription. To date, there are seven STAT family members identi®ed in mammals, designated Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b and Stat6. STATs have diverse normal biological functions, which include roles in cell dierentiation, proliferation, development, apoptosis, and in¯ammation (Akira, 2000; Bromberg et al., 1996; Cressman et al., 1996; Fukada et al., 1996; Hirano et al., 2000; Kaplan et al., 1996a,b; Planas et al., 1997; Smithgall et al., 2000; Stephens et al., 1996; Takeda et al., 1997; Zhong et al., 1994) . Gene knockout studies have de®ned the biological importance of STAT members in normal cells (Akira, 2000) . In particular, Stat2 or Stat3 null mice are embryonic lethal, consistent with a fundamental role for these STAT proteins in development. Mice with targeted Stat1 gene disruption are viable, have impaired response to interferons and show high susceptibility to bacterial and viral infections (Durbin et al., 1996; Meraz et al., 1996) . Furthermore, Stat1 null mice have higher incidence of tumors than normal in response to methylcholanthrene, consistent with Stat1's anti-proliferative activity (Bromberg et al., 1996; Kaplan et al., 1998) . Stat5 knockout mice are viable with phenotypic defects that are tissue-speci®c, including defects in mammary gland development and lactation during pregnancy (Liu et al., 1997) , as well as sexually dimorphic pattern of liver gene expression (Udy et al., 1997) , infertility and immune dysfunction (Teglund et al., 1998) . Because of their diverse biological functions, aberrations in STAT signaling are predicted to have a wide variety of consequences.
STATs and oncogenesis

Requirement for constitutively-active Stat3 in Src oncogenesis
Studies of the molecular basis of oncogenesis by oncoproteins like v-Src have provided insights into changes in intracellular signaling proteins that participate in malignant transformation. The initial ®nding that Stat3 is constitutively activated in v-Src transformation (Cao et al., 1996; Yu et al., 1995) suggested that aberrant STATs may have key roles in oncogenesis, a view validated by more recent observations that constitutive Stat3 activation is required for oncogenic transformation by v-Src (Bromberg et al., 1998; Turkson et al., 1998) . Moreover, a constitutively-activated Stat3 mutant alone is sucient to induce transformation, and cells transformed this way can form tumors in nude mice (Bromberg et al., 1999a) , providing genetic evidence that Stat3 has oncogenic potential. These ®ndings together underscore the ability of abnormal Stat3 activity to induce permanent changes in gene expression programs that ultimately lead to the malignant phenotype. Hence, constitutive Stat3 signaling contributes to transformation by oncogenic tyrosine kinases.
Constitutive STAT activation in transformation by diverse oncoproteins
In addition to v-Src, other transforming tyrosine kinases, such as v-Eyk (Besser et al., 1999) , v-Ros (Zong et al., 1998 ), v-Fps (Garcia et al., 1997 , Etk/ BMX (Wen et al., 1999) , and Lck (Lund et al., 1999; Yu et al., 1997) , all activate Stat3 in the context of oncogenesis (for reviews see Bowman et al., 2000b; Catlett-Falcone et al., 1999a; Garcia and Jove, 1998) . Figure 1 Schematic representation of STAT signaling from a cell surface receptor to the nucleus: molecular targets for disruption of Stat3 signaling. STAT activation is initiated by tyrosine phosphorylation that is mediated by growth factor receptors and/or cytoplasmic protein tyrosine kinases (cPTKs), such as JAKs and Src. Phosphorylation of STATs induces dimerization, which allows STATs to translocate to the nucleus where they bind to consensus STAT binding sequences of target genes and thereby activate gene transcription. Serine phosphorylation of some STATs, including Stat3, by protein serine kinases (PSKs) allows maximal transcriptional activity. Possible sites of disruption of STAT signaling that can be targeted for drug discovery are numbered in parenthesis.
(1) The receptor-ligand interaction is the target of ligand/receptor antagonists, such as IL-6`superantagonists', and receptor-neutralizing antibodies against EGF-R. (2) Protein tyrosine or serine kinases can be targeted by inhibitors, including inhibitors of the tyrosine kinases, EGF-R, JAKs and Src, and the various serine kinases that can phosphorylate Stat3. (3) Physiological protein modulators of STAT activation, including the biological protein inhibitors of STAT activity, such as SOCS or PIAS, and Stat3-interacting protein, StIP1, can be manipulated to alter STAT function. (4) Dephosphorylation of phospho-STATs can be regulated by modulation of protein tyrosine or serine phosphatases, which will in turn diminish the levels of active STATs and the extent of their transcriptional activity. (5) Dimerization of STATs, a crucial event in their activation, can be targeted to interfere with STAT function. (6) Represents STAT translocation to the nucleus, blocking of which can interfere with their presence and transcriptional activity in the nucleus. (7) STAT-coactivator interactions, events that are necessary for STAT transcriptional activity, can be targeted. Of notable importance, constitutive Stat3 activation is also associated with transformation by tumor viruses, including HTLV-1 , polyomavirus middle T antigen (Garcia et al., 1997) , EBV (WeberNordt et al., 1996) , and herpesvirus saimiri (Lund et al., 1997a (Lund et al., ,b, 1999 , that directly or indirectly activate JAKs or Src family tyrosine kinases. Because of its central position downstream of the signaling pathways from protein tyrosine kinases, aberrant Stat3 activity is a key mediator in the transforming process induced by oncogenic tyrosine kinases. In contrast, Stat3-independent mechanisms mediate transformation by oncoproteins that are not tyrosine kinases themselves or do not activate tyrosine kinase signaling pathways, including v-Ras and v-Raf (Garcia et al., 1997) .
With regard to other STATs, constitutive activation of both Stat1 and Stat5 accompanies transformation of pre-B lymphocytes by the v-Abl tyrosine kinase (Danial et al., 1995; Danial and Rothman, 2000) . The transforming BCR-Abl fusion protein also activates Stat1 and/or Stat5 (Carlesso et al., 1996; Chai et al., 1997; Danial and Rothman, 2000; Frank and Varticovski, 1996; Shuai et al., 1996a) and constitutive Stat5 activity is essential for BCR-Abl-induced transformation (de Groot et al., 1999; Nieborowska-Skorska et al., 1999; Sillaber et al., 2000) . Consistent with these ®ndings, mutationally activated forms of Stat5 are sucient to induce certain properties of transformed cells (Yamada et al., 2000) . Thus, Stat3 and Stat5 are the STAT family members with intrinsic oncogenic potential and most strongly associated with human cancer.
Stat3 activation and human diseases
Profile of human tumors that harbor constitutively-active Stat3
Mounting evidence gives credence to Stat3 as a bona ®de mediator of oncogenesis that participates in human malignancies. In the context of human cancer, there is a high frequency of activation of Stat1, Stat3 and Stat5 (Table 1) , with higher incidence of abnormal Stat3 activation in almost all the tumors studied. As the list of human tumors that harbor constitutive Stat3 activity keeps growing, there is increasing chance that many more cases of human cancers will be identi®ed in which Stat3 has prominent role in the induction and/or maintenance of the oncogenic phenotype. Constitutive Stat3 tyrosine or serine phosphorylation has been detected in breast carcinomas (Garcia et al., 1997 (Garcia et al., , 2000 Watson and Miller, 1995) , head and neck squamous cell carcinomas (Grandis et al., 1998 (Grandis et al., , 2000a Song and Grandis, 2000) , as well as lymphomas and leukemias (Catlett-Falcone et al., 1999a ,b, 2000 Coer et al., 2000; Frank et al., 1997; GouilleuxGruart et al., 1996; Weber-Nordt et al., 1996; Zhang et al., 1996c) . Other cases of tumors with constitutive Stat3 activity include prostate, melanoma, pancreas, ovarian and brain (Cattaneo et al., 1998; Florenes et al., 1999; Kirkwood et al., 1999; Lou et al., 2000; Magrassi et al., 1999; Pansky et al., 2000; Schrell et al., 1998 ; L Mora, R Garcia, J Seigne, T Bowman, G Niu, J Pow-Sang, J Diaz, C Muro-Cacho, D Coppola, T Yeatman, J Cheng, S Nicosia, S Shivers, T Landowski, D Reintgen, W Dalton, H Yu and R Jove, unpublished results). These observations make it compelling to examine the role of Stat3 signaling in malignant progression to establish whether the constitutive Stat3 activation present in human tumors is essential for the malignancy. The critical question is whether the association of constitutive Stat3 with human cancers makes it a suitable target for disease intervention.
Other human disease models with constitutive STAT activation Evidence suggests key roles for abnormal or defective activation of STAT signaling pathways in other human diseases. Abnormal STAT signaling associated with defects in activation of JAKs underlies the human immunode®ciency syndromes, human X-linked combined immunode®ciency (XCID), X-linked severe combined immnunode®ciency (XSCID), as well as the less severe form, SCID (Candotti et al., 1997; Heim, 1999; Miyazaki et al., 1994; Russell et al., 1994 Russell et al., , 1995 . Furthermore, constitutive STAT activity is observed in rheumatoid arthritis, where it participates in the early and late stages of the disease, as well as in the inhibitory immune mechanisms in rheumatoid arthritis synovium (Muller-Ladner et al., 2000) . Moreover, links have been established between constitutive STAT signaling and asthma (Sampath et al., 1999) , and with human immunode®ciency virus (HIV) infection where elevated STAT activities are detected in CD4(+) T lymphocytes from HIV patients (Bovolenta et al., 1999) . While these studies present some preliminary observations implicating abnormal STAT signaling in the pathogenesis of these diseases, it is essential to validate the key role of constitutive STAT signaling in order to assess the therapeutic usefulness of anti-Stat3 intervention for each disease type. Moreover, the important role of JAK-STAT signaling in many fundamental biological processes provides basis for evaluating the target validity in human disease cases where abnormal JAKs or STATs are observed (Frank, 1999; Lin et al., 2000; Seidel et al., 2000) .
Validation of Stat3 as target for cancer drug discovery
In considering a`target' for drug discovery, one of the most important issues to be addressed is whether a target hypothetically associated with a disease necessarily represents an appropriate point for new drug intervention. It is vital to ascertain the credibility of the hypothetical target as it relates to its activity in the context of disease and its mechanism of action, and also to establish a cause and eect relationship. The idea is to present a clear de®nition of the position of the target in relation to the disease phenotype (Drews, 2000; Gibbs, 2000) . Consideration of Stat3 as target for cancer drug discovery ideally requires: (i) evidence in cell culture and whole animal models that constitutive Stat3 alone is sucient to induce relevant disease phenotype, and (ii) de®nitive proof from studies in disease-relevant models of cell culture, whole animals, and clinical situations that blocking aberrant Stat3 signaling reverses disease phenotype. Moreover, the molecular mechanism of oncogenesis by Stat3 must be clearly de®ned.
Evaluation of the credibility of Stat3 as a valid target on the basis of present data reveals that the minimum criteria have been exceeded. Application of molecular biology tools, including use of dominantnegative and activated mutant forms of Stat3, and antisense oligonucleotides, in relevant cell culture, animal models and patient samples has provided a high degree of validation for Stat3 as a target for cancer drug intervention. As already pointed out above, an arti®cially-engineered, constitutively-active Stat3 mutant alone induces transformation, and cells transformed by this active Stat3 mutant form tumors in vivo (Bromberg et al., 1999b) . In other key studies that highlight the oncogenic importance of Stat3 and establish a direct link to tumor progression, aberrant Stat3 signaling is obligatory for growth and survival of various human tumor cells, including multiple myelomas (MM), breast carcinomas, head and neck squamous cell carcinomas (HNSCC), the T cell lymphoma mycosis fungoides, and large granular lymphocyte (LGL) leukemia (Catlett-Falcone et al., 1999b; Epling-Burnette et al., 2000; Garcia et al., 2000; Grandis et al., 1998 Grandis et al., , 2000a Nielsen et al., 1997 Nielsen et al., , 1999 ).
Signi®cantly, pharmacological or genetic interruption of constitutive Stat3 signaling inhibits expression of the anti-apoptotic Bcl family members, Bcl-xL, Bcl-2, or Mcl-1, in MM (Catlett-Falcone et al., 1999b) , HNSCC xenograft model (Grandis et al., 2000a) , mycosis fungoides , and LGL leukemia cells (Epling-Burnette et al., 2000) . Inhibition of Stat3 signaling also sensitizes MM to chemotherapy-induced apoptosis , and increases the expression of the pro-apoptotic Bax protein . Importantly, using in vivo tumor models, murine B16 melanoma tumors regress on inhibition of constitutive Stat3 activity by gene therapy with a dominant-negative Stat3 variant (Niu et al., 1999) , making the compelling argument that targeting Stat3 for therapeutic intervention in certain types of human cancers can block tumor growth. Moreover, a number of the Stat3 target genes have been identi®ed, including cyclin D1 (Bromberg et al., 1999b; Sinibaldi et al., 2000) , p21 (Chin et al., 1996; Sinibaldi et al., 2000) , cMyc (Bowman et al., 2000a; Kiuchi et al., 1999; Odajima et al., 2000) , and the Bcl-family members (as already mentioned), which have critical roles in regulating cell proliferation and survival. Indeed, cells Stat 5 (Bowman et al., 2000a; Bromberg et al., 1999a) . Thus, it seems appropriate to infer that by subversion of genetic programs that control normal cell cycle progression and survival signals, constitutive Stat3 induces changes that lead to initiation and/or maintenance of tumorigenesis.
The`cancer-causing' propensity of constitutivelyactivated Stat3 protein, and the evidence of potential clinical bene®ts of blocking constitutive Stat3 signaling, make strong arguments for target validity of Stat3 for drug intervention in cancer therapy. The obvious ®nal question is whether oncogenesis can be induced in a Stat3 null genetic background by oncoproteins, such as v-Src, that induce Stat3 signaling. Gene knockout approaches do not lend themselves readily to biological studies of Stat3 signaling for the reason that early attempts to create Stat3 knockout mice led to embryonic lethality at day 6.5-7.5 (Akira, 1999; Takeda et al., 1997) , an observation consistent with a biological role for Stat3 as mediator of self-renewal (Matsuda et al., 1999; Niwa et al., 1998) , and its absolute requirement for development, growth and survival. Recent eorts have generated conditional Stat3 knockouts (Takeda et al., 1998) , which will allow addressing the question of whether Stat3 null cells are indeed resistant to transformation by the Src oncoprotein.
Signaling pathways that induce constitutive STAT activation as molecular target points for drug discovery Concurrent induction of multiple signaling pathways occurs in response to stimulation by growth factors, cytokines, or oncoproteins, allowing the possibility of complex regulation by cross-talk among signaling pathways. Since there has, as yet, not been identi®ca-tion of a naturally-occurring dominant-positive mutation in the stat3 gene that confers constitutive Stat3 activity and oncogenic ability, it is reasonable to infer that aberrant upstream signaling events are the major driving force for the induction of dysregulated Stat3 signaling that is observed in oncogenesis. Dysregulation of Stat3 signaling can result from persistent input signals from hyperactive ligands or their receptors, constitutive receptor-ligand complexes, aberrant functional properties of speci®c proteins, such as activated c-Src, and tumor viruses that activate Stat3 directly or indirectly. Indeed, studies have con®rmed that aberrant signaling pathways upstream from Stat3 participate in the constitutive Stat3 activation in the context of human cancers (Catlett-Falcone et al., 1999b; Garcia et al., 2000; Grandis et al., 1998 Grandis et al., , 2000a Turkson et al., 1999) . Equally important are downstream eectors of Stat3 activity, which are target gene products with critical functions in oncogenesis. The interplay of these multiple abnormal signaling pathways provides the needed hyperactivity for the induction and/or maintenance of Stat3-mediated oncogenesis. In the context of oncogenesis, current evidence is consistent with Stat3 being a point of convergence for tyrosine and serine kinase signals (Beadling et al., 1996; Ng and Cantrell, 1997; Turkson et al., 1999; Wen et al., 1995) (Figure 1 ).
Tyrosine phosphorylation and constitutive STATs activation
Tyrosine phosphorylation of STATs constitutes an early event in the activation of these transcription factors that is required for their dimerization and DNA-binding activity. Aberrant tyrosine kinase activities of mutant JAKs, growth factor receptors, Src, and tumor viruses that activate tyrosine kinase signals consequentially induce hyperactive Stat3. Indeed, constitutive tyrosine phosphorylation of Stat3 is a necessary requirement for the oncogenic transforming property of this transcription factor (Bromberg et al., 1998 (Bromberg et al., , 1999a Turkson et al., 1998) . This is a highly signi®cant observation that suggests that constitutive upstream tyrosine kinase signals, aberrant Stat3 activity and transformation are interrelated events.
Details of the biochemical mechanisms of induction of constitutive STAT activation are beginning to emerge, and are revealing a cooperation of proteins (with and without tyrosine kinase activity) to induce STATs phosphorylation. In proposed models of activation that are observed for Stat3 and/or Stat1, direct tyrosine phosphorylation by growth factor receptors (Vignais and Gilman, 1999), Src or JAKs (Cao et al., 1996; Chaturvedi et al., 1998; Garcia et al., 2000; Reddy et al., 2000; Zhang et al., 2000) , or a conjunction of all three proteins (Garcia et al., 2000; Zhang et al., 2000) , has been observed. That protein tyrosine kinase inhibitors (PTKIs) block Stat3-mediated oncogenesis, sensitize chemoresistant tumor cells, and induce apoptosis (Catlett-Falcone et al., 1999b; Garcia et al., 2000; Oshiro et al., 2000) , suggests that targeting tyrosine kinases that feed into Stat3 signaling is functionally important in the context of aberrant Stat3 signaling and oncogenesis, and that PTKIs may be clinically useful. This approach for drug discovery is discussed in later sections below.
Serine phosphorylation of STATs
Phosphorylation of a serine residue in the C-terminal transcriptional activation domain of some STATs, corresponding to Ser-727 in Stat3, enhances their transcriptional activity (Decker and Kovarik, 2000; Wen and Darnell, 1997; Wen et al., 1995) . On the identities of the serine kinases, members of the mitogen-activated protein kinases (MAPK) family (Schaefer et al., 1999) , extracellular signal-regulated kinases (ERKs) (Chung et al., 1997; David et al., 1995; Kuroki and O'Flaherty, 1999; Ng and Cantrell, 1997) , c-Jun N-terminal kinase (JNK) (Lim and Cao, 1999; Turkson et al., 1999) and p38mapk (p38) (Gollob et al., 1999; Turkson et al., 1999) , are strong candidate kinases that participate in the serine phosphorylation of Stat1 and Stat3. Given that Stat3 serine phosphorylation is required for maximal activation of its signaling, it is predicted that tyrosine phosphorylation alone is not sucient for the obligatory role of Stat3 signaling in oncogenesis. Indeed, serine phosphorylation is evidently required for the full transforming property of constitutively active Stat3 (Bromberg et al., 1998; Turkson et al., 1999) .
Understanding the signaling pathways that are required for aberrant Stat3 serine phosphorylation identi®es the speci®c signaling components that are necessary for Stat3-mediated transformation. For example, in line with the requirements for constitutive Stat3 (Bromberg et al., 1998; Turkson et al., 1998) and Ras signaling (Stacey et al., 1991) in Src transformation, studies demonstrated cross-talk between Stat3 and Ras signaling pathways (Turkson et al., 1999) . Furthermore, recent studies have con®rmed the concept of obligate cooperation of multiple signaling pathways involving Stat3 and Ras for Src oncogenesis (Odajima et al., 2000) . Application of both genetic and pharmacological tools led to the ®ndings that p38, JNK, and their upstream MAPK kinases are key mediators of Stat3 serine phosphorylation required for Src transformation (Turkson et al., 1999) , identifying these kinases and Ras as possible targets for intervention in constitutive Stat3-mediated oncogenesis. Because serine phosphorylation is important for full STAT activity, the observations that Stat3 is constitutively serine phosphorylated in lymphomas (Frank et al., 1997) and tumor cell lines (Nielsen et al., 1997; Zhang et al., 1995) are signi®cant as they suggest that Stat3 serine phosphorylation has a critical biological role in the pathogenesis of these conditions. Similar to the wide-spread involvement of Stat3 tyrosine phosphorylation in a variety of human tumors, it is likely that future investigation will reveal a wider role of constitutive Stat3 serine phosphorylation in malignant transformation (Gollob et al., 1999) , and provide support for targeting STATs serine phosphorylation signaling for therapeutic intervention.
Interleukin-6/Stat3/Bcl-xL model in human multiple myeloma
In the human MM cell line, U266, Stat3 DNA-binding and transcriptional activities are constitutive (CatlettFalcone et al., 1999b) as a result of aberrant upstream signals. These events are induced by IL-6 and blocked by JAK inhibitors (Catlett-Falcone et al., 1999b) , consistent with a participatory role for the gp130 signaling subunit of IL-6 receptor and a requirement for activities of JAK family kinases in Stat3 signaling (Hirano et al., 2000) . These observations provide a rationale for targeting IL6/gp130 and JAKs for disrupting constitutive Stat3 signaling in the context of MM. Moreover, the ®nding that constitutive Stat3 activity upregulates expression of the bcl-x gene crucial for survival of myeloma cells (Catlett-Falcone et al., 1999b) , provides a direct connection between Stat3 and survival factors like IL-6. Similar links have also been con®rmed for constitutive Stat5 in other tumor models (Dumon et al., 1999; Horita et al., 2000; Nosaka et al., 1999; Silva et al., 1999; Socolovsky et al., 1999) . Furthermore, U266 cells are resistant to chemotherapyor Fas-mediated apoptosis, and become sensitized to drug-induced cell death following inhibition of constitutive Stat3 activity and consequent downregulation of Bcl-xL expression (Catlett-Falcone et al., 1999b; Oshiro et al., 2000) . These studies together describe an anti-apoptotic pathway triggered by protein tyrosine kinase-STAT signaling that contributes to tumor progression and resistance of malignant cells to therapy and provide a basis for targeting Stat3 for certain types of cancer therapy.
Breast carcinoma model
Breast carcinoma cells, including primary tumors and cell lines, have elevated Stat3 activities (Garcia et al., 1997 (Garcia et al., , 2000 Sartor et al., 1997; Watson and Miller, 1995; Xie et al., 1997) , and in some cases, also show elevated EGF receptor (EGF-R) (Sartor et al., 1997) as well as c-Src kinase activities (Garcia et al., 1997) . Studies to de®ne how Stat3 is abnormally induced in breast carcinomas reveal cooperative interactions of Src with JAK tyrosine kinase activities that are required for Stat3 activation (Garcia et al., 2000) . These interactions have been con®rmed in model ®broblast cells that overexpress c-Src and/or EGF-R, and suggest a paradigm of cooperation between Src, JAKs and EGF-R to induce Stat3 activation (Garcia et al., 2000) . The elevated protein expressions or kinase activities of Src, JAKs and/or EGF-R, may increase the chance of constitutive STAT activation. Hence, Src and EGF-R overexpressing breast carcinoma cells are susceptible to growth inhibition and cell death induced by Src or JAK inhibitors (Garcia et al., 2000) . It can be concluded that signaling pathways that lead to constitutive Stat3 activity are required for the survival of breast cancer cells, and this supports the view that drugs that target growth factor receptor/Src/JAKs/ Stat3 signaling may be clinically bene®cial to patients who are positive for Stat3 activities.
Strategies for targeting Stat3 for drug discovery
Knowledge of the mechanisms of constitutive STAT activation and transcriptional activity from the cell surface receptor to the nucleus provides the framework for strategies to target constitutive STAT signaling and their functions. Figure 1 is a schematic representation of signaling pathways leading to STAT activation and transcriptional activity, as well as potential points of interception of STAT function. In focusing on signal transduction mechanisms for drug targeting, the objective is to determine the contribution of each key module in the pathway that participates in the aberrant STAT function. Conceptually, the targeting of upstream modules in signal transduction pathways leading to constitutive STAT activation would impair STAT function and, for certain types of cancers, provide the avenue for intervention to halt the disease. Some of the strategies discussed below are already being developed and are at dierent stages of evaluation. The numbers of the following subheadings correspond to the numbers indicating speci®c sites of intervention in Figure 1. (1) Receptor/ligand antagonists and receptor-neutralizing antibodies Receptor overexpression is frequently associated with many types of cancers, including breast, head and neck, lung, stomach, and ovarian cancers that show elevated expression of the EGF-R family (Aderem, 1993; Hynes, 1993; Reddy et al., 1992) . Where receptor overexpression is connected to disease, use of receptor antagonists could in principle have promising results by blocking receptor activation. Moreover, the functional importance of the ligand-receptor-STAT signal-ing module in biological processes, such as immune responses, provides a rationale for drug targeting of ligands and/or receptors in diseases with causal roles for abnormal STAT activities (see Lin et al., 2000; Seidel et al., 2000 for reviews) . Conceptually, physiological receptors or ligands that activate STAT signaling pathways provide a means to block STAT signaling if it is proven that abnormal receptor or ligand activity is the stimulus for the constitutive STAT activation. Receptor or ligand antagonists include molecules that are structurally related to but lack the intrinsic activating property of the physiological ligand and possess higher anity for receptor. The potential of this approach has been demonstrated using the IL-6 superantagonist', Sant7, that blocks constitutive Stat3 activation in U266 myeloma cells (Catlett-Falcone et al., 1999b) and inhibits cell growth (Demartis et al., 1996; Petrucci et al., 1999) . Moreover, current clinical applications of this approach in certain types of human disease conditions, including the use of recombinant tissue necrosis factor receptor in treatment of rheumatoid arthritis (Moreland et al., 1997 ; for review, see Seidel et al., 2000) , make a compelling argument for evaluating its usefulness for cancer therapy. However, considerably more studies remain to be done to show the correlation of growth inhibition of tumors in whole animals with block of constitutive Stat3 activity using receptor or ligand antagonists.
The application of monoclonal antibodies for the treatment of diseases, including human cancers, has received widespread recognition with the advent of recombinant antibody technology. In principle, the binding of neutralizing antibodies to their respective epitopes on receptors disrupts receptor interaction with its physiological ligand, and provides a means of targeted therapy that focuses on modulating the function of receptors that may be overexpressed on cancer cells. Therapeutic antibodies can be adopted as a single treatment, or as a combined therapy with traditional chemotherapy or novel compounds that inhibit various steps of signal transduction pathways (Fan and Mendelsohn, 1998) . Where a link is established between receptor activity and disease, anti-receptor monoclonal antibodies are eective against disease conditions, such as growth inhibition by anti-EGF-R antibody of transplanted human tumors (Azemar et al., 2000; Baselga et al., 1998; Pegram et al., 1999; Pietras et al., 1998) , and metastatic cancer (Baselga et al., 1996; Pegram et al., 1998) .
As discussed in preceding sections, certain key components of signal transduction pathways upstream of Stat3 are critical for constitutive Stat3 activation (Catlett-Falcone et al., 1999b; Garcia et al., 2000; Grandis et al., 1998 Grandis et al., , 2000b Turkson et al., 1999; Zhang et al., 2000) . In principle, similar to ligand antagonists, antibody targeting of cell surface receptors that are determined to be sources of signaling for Stat3 activation would be expected to impede binding of ligand, impair induction of the signaling, and block constitutive activation of Stat3 and Stat3-mediated oncogenesis. Use of receptor neutralizing antibody, for example, C225, anti-EGF-R antibodies, and herceptin, anti-HER2 antibodies, as therapeutic approaches is currently being exploited in clinical trials (Baselga et al., 1996 (Baselga et al., , 1998 (Baselga et al., , 2000 . Given that EGF-R mediates Stat3 activation in HNSCC (Grandis et al., 1998 (Grandis et al., , 2000a Song and Grandis, 2000) , it would be presumed that clinical responses in HNSCC to therapeutic C225 is a function of inhibition of EGF-R-mediated constitutive activation of downstream signaling components, including Stat3. However, the validity of this view must be critically evaluated by determining the degree of Stat3 activation before and after antibody therapy.
(2) Tyrosine or serine kinase inhibitors Protein kinases as targets represent one of the most exploited approaches for therapeutic intervention, and the degree of success in this area is demonstrated in the number of ongoing clinical trials (Ben-Bassat and Klein, 2000; Fry, 2000; Levitzki, 1999; Miknyoczki et al., 1999) . Considerable eorts have gone into designing compounds that inhibit activities of tyrosine kinases that participate in STAT signaling. Targeting kinases that participate in STAT signaling for intervention of tumor progression can be very eective if it is shown that aberrant STAT signaling is the result of dysregulated upstream tyrosine kinases. Inhibition of tyrosine kinase activity inhibits growth of breast cancer cells (Garcia et al., 2000; Reddy et al., 1992) and it correlates with inhibition of constitutive Stat3 activity in cultured tumor cells (Garcia et al., 2000) . Furthermore, inhibition of Src, JAKs or Bcr-Abl kinasemediated constitutive Stat3 or Stat5 signaling induces apoptosis in MM or CML cells (Catlett-Falcone et al., 1999a ,b, 2000 Horita et al., 2000; Huang et al., 2000; Sillaber et al., 2000) , and inhibits growth of prostate cancer cells ; L Mora, R Garcia, J Seigne, J Pow-Sang, J Diaz, A Kraker and R Jove, unpublished results). Antitumor activity against human tumor xenografts using an EGF-R tyrosine kinase inhibitor, PD 0169414 (Vincent et al., 2000) , provides compelling support for targeting tyrosine kinases for therapeutic intervention in tumor patients. Other protein tyrosine kinases already discussed above that are involved in STAT signaling and are potential targets for drug discovery include Src, Eyk and Btk families. The challenge is to determine which of these kinases is suitable for targeting that would oer the most promising clinical bene®ts.
Because of the key role of serine phosphorylation for maximal transcriptional activity of some STATs (for review, see Decker and Kovarik, 2000) , it is predicted that inhibition of this modi®cation would be sucient to impair STAT activity. Variants of STATs that are mutated at the speci®c serine residues show signi®cant inhibitory activity consistent with dominant-negative eects against transcriptional activity of some STATs (Bromberg et al., 1996 (Bromberg et al., , 1998 Caldenhoven et al., 1996; Turkson et al., 1998) . That such dominant-negative mutant forms of STATs block the biological eects of wild-type counterparts (Bromberg et al., 1996 (Bromberg et al., , 1998 Turkson et al., 1998) , underscores the functional importance of serine phosphorylation. Moreover, modi®cation of the STAT serine phosphorylation signals via pharmacological agents that block STATspeci®c serine kinases has shown promising eects. For example, pharmacological inhibition of p38 activity that is required for Stat3 serine phosphorylation and transcriptional activity blocks transformation induced by v-Src (Turkson et al., 1999) .
The application of protein kinase inhibitors has signi®cant implications for chemotherapy for those cancers that are positive for Stat3 activity. Currently, one prototype drug that has been widely used is the tyrphostin, AG490, a JAK inhibitor (Levitzki, 1999) . This compound not only blocks Stat3 signaling, but also inhibits Stat3-mediated Bcl-xL induction, induces apoptosis, and possesses antitumor activity (Burdelya et al., 2000; Catlett-Falcone et al., 1999b) . Further structure-activity relationship studies should yield more eective and selective inhibitors of STAT protein tyrosine or serine kinases that can be therapeutically useful for Stat3 positive cancers.
(3) Physiological protein modulators of STAT activation
Physiological protein inhibitors of STAT signaling comprise endogenous proteins that directly or indirectly downregulate STAT activation. This family of inhibitors includes the cytokine-inducible SH2-containing (CIS) proteins (same as suppressor of cytokine signaling (SOCS), JAK binding protein (JAB) and STAT-induced STAT inhibitor (SSI)), as well as the protein inhibitors of activated STATs (PIAS) (Endo et al., 1997; Hilton, 1999; Kovanen and Leonard, 1999; Naka et al., 1997; Shuai, 2000; Starr and Hilton, 1999) . The CIS family regulates STAT signaling at the level of cytokine receptors or JAKs, although the speci®city of each family member may not be limited only to these targets. On the other hand, the PIAS family directly interacts with activated STATs, interfering with their DNA-binding activity, and inhibiting gene transcription (Shuai, 2000) . Knowledge from the mechanisms of action of these biological inhibitors could help in the design of molecules that can mimic their actions and inhibit STAT function. Pharmacological or small molecule mimics of SOCS or PIAS that would eectively`turn-o' the signaling pathways involved in the constitutive STAT activation, and thus downregulate Stat3 signaling, would have wide applicability to Stat3-senstive tumors.
A newly identi®ed cytoplasmic Stat3-interacting protein, StIP1, acts a scaold protein that regulates ligand-dependent Stat3 activation (Collum et al., 2000) . Unlike the others in this class of proteins that interact with STATs, StIP1 binds both inactive Stat3 and JAKs in a hypothetical Stat3-StIP1-JAKs trimolecular complex proposed to facilitate Stat3 activation. However, initial studies show that the expression of StIP1 mutant forms that encompass only the STAT-binding domain inhibit ligand-induced Stat3 tyrosine phosphorylation, DNA-binding and transcriptional activities (Collum et al., 2000) . Thus, critical biochemical analyses of the interaction of Stat3 with StIP1 may provide key structural information necessary for the design of peptides or mimics that can directly interact with Stat3 in a high anity manner and inhibit its activation.
(4) Modulation of phosphatases
Protein phosphorylation is fundamentally important in cellular processes as it regulates the functional activities of signaling proteins. Overall, tyrosine phosphorylation states of proteins re¯ect the relative ratio of activities of protein tyrosine kinases and protein tyrosine phosphatases (PTPase). Similarly, protein serine phosphorylation and dephosphorylation by kinases and phosphatases, respectively, maintain physiological balance of phosphoserine states of proteins. Activities of PTPase and phosphoserine phosphatase counterparts represent an essential regulatory mechanism that can be exploited for therapeutic bene®ts. With respect to STATs, studies with inhibitors of protein phosphatases reveal the importance of protein dephosphorylation in modulating STAT functions (David et al., 1993; Haque et al., 1995; Woetmann et al., 1999) . Two PTPases, SHP-1 and SHP-2, as well as a protein serine/threonine phosphatase, PP2A, are strongly implicated in STAT signaling, including Stat1, Stat3 and Stat5 (Ram and Waxman, 1997; Schaper et al., 1998; Shuai et al., 1996b; Stofega et al., 1998; Strehlow and Schindler, 1998; Woetmann et al., 1999; Yu et al., 2000) . Among others, SHP-1 associates with activated Stat5 in the nucleus in a ligand-dependent manner (Ram and Waxman, 1997), and SHP-2 enhances cell growth and development by downregulating IFN-activated Stat1 (You et al., 1999) . Moreover, modulation of activities of PTPases with non-speci®c inhibitors, such as vanadate, are sucient to upregulate active STAT levels , and PP2A participates in induction of constitutive Stat3 serine phosphorylation and subcellular distribution in cutaneous T cell lymphoma .
In principle, it is possible to alter STAT function at the level of protein phosphatases. In the context of constitutive Stat3 activity in oncogenesis, the intent is to design compounds that promote protein phosphatase activities that are capable of downregulating phospho-Stat3. The concern of this approach, however, is potential non-speci®c eects from regulation of activities of other phosphatase substrates. If it can be established that there are speci®c phosphatases that preferentially dephosphorylate active Stat3, it would be easier to achieve selectivity among the dierent phosphatases.
(5) Disrupters of STAT dimerization
Dimerization via reciprocal phosphotyrosine-SH2 interactions is a key event in the activation of STATs. Active STATs bind to DNA as dimers (Chen et al., 1998) , demonstrating the importance of this step for STAT function. Moreover, dimerization of STATs is also critical for their nuclear translocation and gene transcriptional activity (Becker et al., 1998; Chen et al., 1998; Horvath et al., 1995; Schindler et al., 1992; Shuai et al., 1992) . Thus, manipulations that do not allow dimerization, such as use of STAT mutants with a tyrosine to phenylalanine substitution, render the protein incapable of forming dimers, binding DNA and inducing gene transcription (Bromberg et al., 1998) . Disruption of Stat3 dimer formation therefore provides an eective approach of targeting this protein for blocking its signaling activity and functional eects. To interfere with STAT dimerization, ideal compounds should possess certain characteristics, including a stronger anity for STAT monomer for a more favorable and cohesive interaction that generates a heterocomplex of STAT-compound over STAT-STAT dimers.
Concerning the ability of arti®cial compounds to disrupt preformed STAT dimers, in principle a much more dicult step, it would be predicted that à super' high anity for STAT monomer might allow the arti®cial compound to associate with pre-existing dimers of STAT. When this happens, it can be speculated that one or both of these events can take place: (i) the association might facilitate the dissociation of STAT dimers and the preferential formation of a heterodimeric complex involving STAT and compound; or (ii) the association would generate a heterotrimeric complex that would interfere with the ability of STAT dimer to eectively interact with coactivators and bind DNA. In terms of chemical design, disrupters of STAT dimerization could be SH2-like peptides with high anity for the phosphotyrosine region of STATs, peptides with phosphotyrosine sequences, or small peptide mimetics that are speci®c for the SH2 sequence of STATs. Dierences in sequences for the individual STAT members can be exploited to yield compounds that have selectivity for speci®c STATs. Information on the crystal structure of STAT dimers bound to DNA (Becker et al., 1998; Chen et al., 1998) should assist in the design of small molecules that can disrupt dimers of STATs. Such small molecules would provide leads for design of therapeutically useful compounds for clinical purposes.
(6) Inhibitors of STAT translocation
Following dimerization, STATs translocate into the nucleus and bind to speci®c regulatory sequences of responsive genes to induce gene transcription. The mechanisms of STAT translocation are not fully understood. Initial evidence of how the structure of STAT proteins might aect translocation suggests that the N-terminal region contains a nuclear translocation signal (Strehlow and Schindler, 1998) , and the critical tyrosine residue of some STATs is required for (Sekimoto et al., 1996) but does not guarantee nuclear translocation (Ali and Ali, 1998) . STAT tyrosine phosphorylation is therefore not sucient for translocation. On the question of STATs possessing authentic nuclear localization sequences (NLS), this is not widely believed to be the case (Johnson et al., 1998b) , raising the possibility of a distinct nuclear translocation mechanism whose induction signal originates from STAT proteins. There is some evidence that the phosphorylation of a critical tyrosine residue of the activating receptor is essential in recruiting intracellular components that regulate interactions of STAT dimers with cellular proteins in the cytoplasm, events that may modulate STAT nuclear translocation (Ali and Ali, 1998) . Furthermore, it is also postulated based on preliminary evidence that certain cytokines or their receptors possess functional NLS, and that complexes of the cytokine-receptor might act as chaperones that associate with and transport STATs into the nucleus (Johnson et al., 1998a,b) . For example, it has been reported that interferon-g (IFNg) possesses a NLS whose function is required for the biological role of IFNg, possibly through Stat1 transcriptional activity (Johnson et al., 1998a,b) . Although this intriguing observation remains to be con®rmed in other systems, it suggests that blocking components that confer translocation of STATs into the nucleus can attenuate their biological eects.
Thus, understanding the details of translocation mechanisms of individual STATs, including de®ning the key points of interaction between STATs and molecular components of the translocation machinery complex, would provide the necessary information for design of selective compounds that interfere with one of the critical events of STAT function. Small molecule mimics of essential structural regions of key components of the translocation machinery could suciently disrupt STAT translocation and eectively block STAT function. Distinct mechanisms of translocation for individual STATs could allow for selective targeting of speci®c STAT members. In the context of human diseases associated with causal roles for constitutive STATs, the approach of blocking STAT nuclear translocation would provide another avenue for blocking STAT function as the cause of disease.
(7) Direct blocking of STAT DNA-binding and transcriptional activity
Interactions with speci®c sequences in the promoter regions of responsive genes allow STATs to induce gene expression as transcription factors. The transcriptional activity of STATs requires that they physically interact with the promoter sequences. Knowledge of the crystal structure of STAT dimer bound to its cognate DNA sequence would reveal the critical amino acid residues that are required for physical interaction with DNA. This information could be the basis for rational design of arti®cial competitors of STAT DNAbinding activity. Speci®c cooperative contacts of STATs with transcription coactivators, p48 (Bluyssen and Levy, 1997; Martinez-Moczygemba et al., 1997), CBP/p300 (Paulson et al., 1999; Zhang et al., 1996b) , Sp1 (Cantwell et al., 1998) , or with nuclear adaptor proteins (Rhodes et al., 2000) , are also essential for their transcriptional activity (Bromberg and Darnell, 2000) . Regions of STATs identi®ed to participate in cooperative interactions with other proteins include the coiled-coil domain and the C-terminal region (Paulson et al., 1999) distant from the DNA contact sites . The conserved N-terminal regions of some STATs are also required for cooperative DNA binding of two STAT dimers (Xu et al., 1996) , giving STATs the ability to induce genes with variations of the consensus binding site in promoters even though the anity for binding to such sequences may be weak.
Mutational analysis of amino acids in the N-terminal region of STATs should de®ne the residues that are obligatory for cooperative interactions between STATs and coactivators for their functional eects. The requirement of STAT transcriptional activity for coactivators, or nuclear adaptors in some cases, suggests it is possible to modulate the transcriptional activity and biological functions of some STATs by using small molecule mimics of coactivators that would interfere with the cooperative interactions. The mimics of natural coactivators that can interact with STATs would lack the positive modulation eect. Thesè pseudo-coactivators' could be engineered to possess higher anity for Stat3 since they must compete with natural coactivator molecules. In principle, pseudocoactivators would block the biological eects of STATs by substituting for natural coactivators and suppressing the transcriptional activities of Stat3, analogous to the block of IFN-g-Stat1-mediated gene activation and biological eects by a mutant adenovirus E1A protein (Look et al., 1998) . The competitive pseudo-coactivators could be designed taking advantage of the uniqueness of the point of interaction of these molecules with the speci®c STAT member that would allow preferential high-anity interaction that confers speci®city. For example, in the interaction of Stat1 with CBP/p300, or Stat3 with c-Jun, two contact regions have been identi®ed that confer speci®city of the interaction between each group of two proteins (Shuai, 2000; Zhang et al., 1996b Zhang et al., , 1999 . Requirement for these cooperative interactions for stable complexes of STATs with DNA (Bluyssen and Levy, 1997) suggests that it is possible to annul the eects of constitutive Stat3 activity by ectopically expressing modi®ed coactivators that no longer confer the necessary interactions with Stat3 for eective binding to DNA and gene transcription. Antisense oligonucleotides can be eective molecular biological tools to investigate the function of a protein in a cell. The application of antisense is a simple, ecient and target-selective approach, as antisense sequence-speci®city modulates gene expression and discriminately targets the biological functions of the gene product (Agrawal and Kandimalla, 2000) . The application of antisense technology is already forging ahead in the number of existing clinical trial cases (Cunningham et al., 2000; Green et al., 2000; Marcusson et al., 1999; Nemunaitis et al., 2000; Yuen et al., 1999) . Experimentally, antisense oligodeoxynucleotide (ODN) against HER2/neu inhibits human tumor xenografts implanted in nude mice, and when used in combination with conventional chemotherapy shows enhanced growth inhibitory eects on tumor cell lines that overexpress HER2/neu (Roh et al., 1999) . With regard to Stat3 signaling, antisense targeting of Stat3 signi®cantly inhibited growth of squamous epithelial cells (Grandis et al., 1998 (Grandis et al., , 2000a and B lymphoma cells (Karras et al., 2000) . Although this is still at the experimental stage, it makes compelling argument for examining the therapeutic bene®ts of antisense against Stat3 in cases where constitutive Stat3 activity is linked to disease pathogenesis.
Similar to the application of antisense, use of decoy ODNs harboring protein DNA-binding sites is in principle an approach worthy of consideration. Evidence shows that activated STAT proteins bind to sequence-speci®c regions in the promoters of genes in the nucleus. In some cases, sequences are unique for binding by speci®c STAT members, such as the sequence present in the promoter region of the acute phase response protein, C-reactive protein, which is speci®c for Stat3 (Zhang et al., 1996a) . The ectopically expressed excess high-anity STAT-speci®c ODNs binding sites in cells would theoretically compete with physiological gene promoters that are STAT target genes. The prediction is that because of the higher anity and molar excess of ODNs in cells, the exogenous DNA sequence would eectively sequester active STATs and signi®cantly reduce in vivo available levels that can bind natural promoter sequences. In theory, this phenomenon of`soaking-up' active STAT proteins by decoy ODNs would result in suppression of gene transcription and diminished biological eects. The decoy ODNs approach has been tested in cell culture as well as whole animal studies with respect to other systems (Amoah-Apraku et al., 2000; Griesenbach et al., 2000; Kuratsukuri et al., 1999; Tomita et al., 1999) . With regard to STAT signaling, the decoy ODNs approach has been utilized to eectively block cellular responses (Huang et al., 1999; Wang et al., 2000) , suggesting its potential practical usefulness.
Analogous to the preceding two approaches, use of dominant-negative interfering mutant forms of proteins to block functional eects of normal proteins has also shown considerable promise. Signi®cantly, the introduction of a dominant-negative Stat3 gene blocks growth and induces regression of Stat3-dependent murine melanoma tumors in nude mice compared to control expression vector alone (Niu et al., 1999) . The anti-tumor eects of this dominant-negative Stat3 gene in B16 melanoma tumors establish the potential clinical usefulness of this gene therapy approach in cancers that are positive for constitutive Stat3 activity. Overall, gene-directed targeting is highly target-selective and has the advantage of being more speci®c than conventional drugs. The major challenge of this approach is the relative ineciency of introducing genes encoding dominant-negative proteins into cells. However, in the case of Stat3 dominant-negative gene therapy, a transfection eciency of 10 ± 15% is sucient to induce massive tumor cell killing involving more than 90% tumor cell death (Niu et al., 1999) . This potent bystander' eect may be the key to successful dominant-negative Stat3 gene therapy of human tumors. The mechanistic basis for this bystander eect is currently under investigation.
Conclusions
Analyses of human tumors are revealing increasing numbers that are positive for constitutive Stat3 activity. This is a trend that is likely to continue as we expand the tumor types that are assayed for constitutive Stat3 activation. Moreover, initial assessment of the extent of Stat3 activation in dierent stages of human malignancies suggests a correlation between the level of Stat3 activation and tumor progression. The key is to validate these patterns to provide a basis for classifying tumors relative to levels of Stat3 activity. In particular, the intent is to evaluate Stat3 as a molecular marker for early detection of certain types of cancers, and also as a prognostic indicator for determining the aggressiveness of cancer types and their response to dierent treatment modalities. Reliable data on Stat3 activity in tumors that were previously Stat3-negative and responsive to chemotherapy but eventually fail to respond to therapy on relapse would provide any correlation there might be between onset of constitutive Stat3 activation and aggressiveness of tumors on relapse, as well as chemosensitivity. These objectives call for screening of constitutive Stat3 activity in tumors prior to selection of treatment type and following the progress of treatment in patients. Ultimately,`customized' therapies may be devised based on the molecular STAT pro®le. Such custom therapy approaches would take into account the stage of the tumor and appropriately factor in the level of constitutive Stat3 activity as it relates to the disease progression. Lastly, where details of the mechanism of constitutive Stat3 activation are de®ned in the context of tumor type, novel therapeutic approaches based on molecular and/or pharmacological modulation of the components that are critically involved in the constitutive Stat3 signaling pathway would substantially broaden the available eective treatment modalities for cancer.
